TY - JOUR
T1 - Intraocular pressure variations
T2 - Causes and clinical significance
AU - Sit, Arthur J.
N1 - Funding Information:
Supported by: This review was supported by the Mayo Foundation for Medical Education and Research in Rochester, Minn., and an unrestricted departmental grant from Research to Prevent Blindness in New York, N.Y. A.J.S. is the recipient of the Robert & Helen Schaub Special Scholar Award from Research to Prevent Blindness.
Publisher Copyright:
© 2014 Canadian Ophthalmological Society.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Reduction of intraocular pressure (IOP) is the only known effective treatment for glaucoma. However, IOP is a highly variable and dynamic parameter, undergoing virtually constant changes from numerous factors, including body position and circadian rhythms. Despite this variability, evidence for the efficacy of IOP reduction in glaucoma is based on studies designed to assess mean IOP and not IOP variations. Post hoc analysis of data from major clinical trials has suggested that IOP variations may be an independent risk factor for the development of glaucoma or glaucomatous progression, at least in some patients, but the evidence is incomplete and further studies are required. In the interim, judicious selection of existing therapies can help to minimize IOP variations. In general, therapies that improve outflow instead of suppressing aqueous humor production result in more stable IOP. However, new technology to allow better monitoring of IOP, ideally in a continuous 24-hour manner, is required to fully understand the role of IOP variations in glaucoma.
AB - Reduction of intraocular pressure (IOP) is the only known effective treatment for glaucoma. However, IOP is a highly variable and dynamic parameter, undergoing virtually constant changes from numerous factors, including body position and circadian rhythms. Despite this variability, evidence for the efficacy of IOP reduction in glaucoma is based on studies designed to assess mean IOP and not IOP variations. Post hoc analysis of data from major clinical trials has suggested that IOP variations may be an independent risk factor for the development of glaucoma or glaucomatous progression, at least in some patients, but the evidence is incomplete and further studies are required. In the interim, judicious selection of existing therapies can help to minimize IOP variations. In general, therapies that improve outflow instead of suppressing aqueous humor production result in more stable IOP. However, new technology to allow better monitoring of IOP, ideally in a continuous 24-hour manner, is required to fully understand the role of IOP variations in glaucoma.
UR - http://www.scopus.com/inward/record.url?scp=84920057590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920057590&partnerID=8YFLogxK
U2 - 10.1016/j.jcjo.2014.07.008
DO - 10.1016/j.jcjo.2014.07.008
M3 - Article
C2 - 25433736
AN - SCOPUS:84920057590
SN - 0008-4182
VL - 49
SP - 484
EP - 488
JO - Canadian Journal of Ophthalmology
JF - Canadian Journal of Ophthalmology
IS - 6
ER -